株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ChemoCentryx, Inc. : 製品パイプライン分析

ChemoCentryx, Inc. - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 214147
出版日 ページ情報 英文 56 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.97円で換算しております。
Back to Top
ChemoCentryx, Inc. : 製品パイプライン分析 ChemoCentryx, Inc. - Product Pipeline Review - 2016
出版日: 2016年09月30日 ページ情報: 英文 56 Pages
概要

ChemoCentryx, Inc. (ChemoCentryx) はバイオ製薬会社として、自己免疫疾患や炎症、癌などの治療のための経口投与薬の開発を行っています。

当レポートでは、ChemoCentryx, Inc.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

ChemoCentryx, Inc.の基本情報

  • ChemoCentryx, Inc.の概要
  • 主要情報
  • 企業情報

ChemoCentryx, Inc.:R&Dの概要

  • 主な治療範囲

ChemoCentryx, Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

ChemoCentryx, Inc.:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第?相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第?相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ
  • ■ChemoCentryx, Inc.:開発段階が不明のパイプライン製品
  • 開発段階が不明の製品/併用療法モダリティ

ChemoCentryx, Inc.:薬剤プロファイル

  • vercirnon sodium
  • CCX-140
  • CCX-168
  • CCX-354
  • CCX-507
  • CCX-872
  • CCX-1378
  • CCX-1641
  • CCX-6239
  • CCX-650
  • CCX-721
  • CCX-771
  • 未公表の症状向け CCR1 拮抗小分子
  • 乾癬向け CCR6 拮抗小分子
  • 自己免疫疾患・腫瘍学・肝臓疾患向け CXCR6 拮抗小分子
  • 腫瘍学・自己免疫疾患向け CCR および CXCR 拮抗小分子
  • CCR2-3G
  • CCR9-3G
  • CCX-956

ChemoCentryx, Inc.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

ChemoCentryx, Inc.:最近のパイプライン動向

ChemoCentryx, Inc.:休止中のプロジェクト

ChemoCentryx, Inc.:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
  • CCX-832
  • vercirnon sodium

ChemoCentryx, Inc.:本社と子会社の所在地

付録

図表

目次
Product Code: GMDHC08138CDB

Summary

Global Markets Direct's, 'ChemoCentryx, Inc. - Product Pipeline Review - 2016', provides an overview of the ChemoCentryx, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by ChemoCentryx, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of ChemoCentryx, Inc.
  • The report provides overview of ChemoCentryx, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses ChemoCentryx, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features ChemoCentryx, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate ChemoCentryx, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for ChemoCentryx, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding ChemoCentryx, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • ChemoCentryx, Inc. Snapshot
    • ChemoCentryx, Inc. Overview
    • Key Facts
  • ChemoCentryx, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • ChemoCentryx, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • ChemoCentryx, Inc. - Pipeline Products Glance
    • ChemoCentryx, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • ChemoCentryx, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • ChemoCentryx, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • ChemoCentryx, Inc. - Drug Profiles
    • CCR-23G - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCR-93G - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCX-140 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCX-168 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCX-354 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCX-507 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCX-6239 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCX-650 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCX-771 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCX-872 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCX-9588 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCX-991 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize CCR1 for Undisclosed Indication - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize CXCR6 for Autoimmune, Oncology and Liver Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Target C5aR for Undisclosed Indication - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize CCR and CXCR for Oncology and Autoimmune Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vercirnon sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • ChemoCentryx, Inc. - Pipeline Analysis
    • ChemoCentryx, Inc. - Pipeline Products by Target
    • ChemoCentryx, Inc. - Pipeline Products by Route of Administration
    • ChemoCentryx, Inc. - Pipeline Products by Molecule Type
    • ChemoCentryx, Inc. - Pipeline Products by Mechanism of Action
  • ChemoCentryx, Inc. - Dormant Projects
  • ChemoCentryx, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • CCX-832
      • vercirnon sodium
  • ChemoCentryx, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • ChemoCentryx, Inc., Key Facts
  • ChemoCentryx, Inc. - Pipeline by Indication, 2016
  • ChemoCentryx, Inc. - Pipeline by Stage of Development, 2016
  • ChemoCentryx, Inc. - Monotherapy Products in Pipeline, 2016
  • ChemoCentryx, Inc. - Phase III, 2016
  • ChemoCentryx, Inc. - Phase II, 2016
  • ChemoCentryx, Inc. - Phase I, 2016
  • ChemoCentryx, Inc. - Preclinical, 2016
  • ChemoCentryx, Inc. - Discovery, 2016
  • ChemoCentryx, Inc. - Pipeline by Target, 2016
  • ChemoCentryx, Inc. - Pipeline by Route of Administration, 2016
  • ChemoCentryx, Inc. - Pipeline by Molecule Type, 2016
  • ChemoCentryx, Inc. - Pipeline Products by Mechanism of Action, 2016
  • ChemoCentryx, Inc. - Dormant Developmental Projects,2016
  • ChemoCentryx, Inc. - Discontinued Pipeline Products, 2016
  • ChemoCentryx, Inc., Subsidiaries

List of Figures

  • ChemoCentryx, Inc. - Pipeline by Top 10 Indication, 2016
  • ChemoCentryx, Inc. - Pipeline by Stage of Development, 2016
  • ChemoCentryx, Inc. - Monotherapy Products in Pipeline, 2016
  • ChemoCentryx, Inc. - Pipeline by Top 10 Target, 2016
  • ChemoCentryx, Inc. - Pipeline by Route of Administration, 2016
  • ChemoCentryx, Inc. - Pipeline by Molecule Type, 2016
  • ChemoCentryx, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top